NodThera

Spotted on the trading floor at the NYSE! Great to see NodThera on the screens at the New York Stock Exchange following our inclusion in Fierce Biotech's ‘Fierce 15’ 2024 special report. #NodThera #Fierce15 #Innovation #NYSE #Biotech #NLRP3

We are delighted to have been named by Fierce Biotech as one of its ‘Fierce 15’, in the 2024 special report highlighting the most innovative and promising #biotech companies in the industry. This recognition follows the significant progress we have made towards realizing the full potential of targeting the #NLRP3 #inflammasome and our bright future as we progress the clinical development programs in #CardiovascularDisease, #Obesity and #Neuroinflammation. Learn more about why we stand out here: https://lnkd.in/eXVdVv4z #NodThera #Fierce15 #Innovation 

Please join us in extending a warm welcome to Greg Chow, NodThera’s new Chief Financial and Business Officer! Greg brings over 25 years of public and private company leadership experience, including deep expertise in capital markets, #DrugDevelopment and business development. Over the course of his career, he helped lead the execution of major financing rounds, including a $254 million Series F fundraise at Freenome Holdings, where he most recently served as CFO. Find out more about Greg’s #appointment and experience here: https://lnkd.in/e6RMyFfH #NewHire #NeuroInflammation #WelcomeToTheTeam #NLRP3

We are pleased to share NodThera’s latest research publication detailing the preclinical pharmacology of our clinical-stage drug candidate, NT-0796, which has successfully completed two Ph1b/2a clinical studies in Parkinson’s disease and obese patients at cardiovascular risk. 🔬 Key Highlights: Mechanism of Action: NT-0796 is metabolized by carboxylesterase-1 (CES1) to produce NDT-19795, which inhibits the NLRP3 inflammasome. Potency: In human monocytes/macrophages, NT-0796 demonstrates superior potency compared to NDT-19795 alone. Cellular Dynamics: NT-0796 accumulates rapidly within cells, reaching higher concentrations than those in the medium, followed by conversion to NDT-19795 in CES1-expressing cells. Pharmacodynamics: NT-0796 acts as an effective vehicle to deliver NDT-19795, providing a robust NLRP3 inhibition by leveraging the dynamics of CES1 metabolism. This study underscores our commitment to developing pioneering treatments targeting #NLRP3 #inflammasome-related diseases. Dive into the full study to learn more: https://lnkd.in/eaYk2f5f

In a recent discussion with Jill Drachenberg from BioSpace, Alan Watt, our President & Chief Scientific Officer, highlights NodThera’s innovative approach to addressing chronic neuroinflammation, marking a potential game-changer in Parkinson’s treatment. Our #NLRP3 #inflammasome inhibitors show promise not only in halting brain inflammation in Parkinson’s disease but also in addressing a range of chronic inflammatory conditions, including #obesity and #cardiovascularDisease. Read more here: https://lnkd.in/es_g27ay #NodThera #Neuroinflammation #DrugDiscovery #Biotech

We are excited to share that tomorrow, our Chief Scientific Officer, Alan Watt, will speak at the Future of Healthcare Investment Forum 2024 organized by LSEG (London Stock Exchange Group). He will join an expert panel on Metabolic Diseases to share insights from our pioneering research. Don't miss this opportunity to learn how we are shaping the future of healthcare. Follow this link to register:   https://lnkd.in/dGbknNHf #HealthcareInnovation #MetabolicDiseases #NodThera #FutureOfHealthcare #InvestmentForum2024 #Biotech

Today we reached another exciting clinical milestone in our journey to deliver a paradigm shift in the treatment of chronic inflammatory diseases, announcing positive data from a Phase Ib/IIa #cardiovascular risk study of our lead brain-penetrant #NLRP3 #inflammasone inhibitor candidate, NT-0796. The trial met its primary endpoint, demonstrating a highly statistically significant and rapid reduction of C-reactive protein (CRP), a key biomarker of chronic #cardiometabolic inflammatory diseases, in inflamed obese subjects dosed with NT-0796 compared to placebo. The study also saw reductions in body weight, the most pronounced among high-risk subgroups, supporting the anti-obesity potential of the molecule. Preparations are now underway for a Phase II #obesity study alongside other Phase IIa studies in additional cardiometabolic diseases and #ParkinsonsDisease. Learn more: https://bit.ly/4aYdBPR #NeuroInflammation #DrugDiscovery #Biotech

We are pleased to welcome Daniel Swisher as Chief Executive Officer! Dan joins the team with more than 30 years of leadership expertise in the #LifeSciences industry. During his career, he has led the advancement and commercialization of novel therapeutics in multiple therapeutic areas, including #neuroscience and #RareDiseases, and has significant experience in driving cross function, high-performing teams and relationship building. NodThera’s founder and interim CEO, Alan Watt, becomes our President and CSO, responsible for growing the Company’s R&D organisation and strengthening our world-leading position in #NLRP3 #inflammasome research. Find out more here: https://lnkd.in/d4vYKka7 #Appointment #NewHire #NeuroInflammation #WelcomeToTheTeam

We are pleased to share NodThera’s latest research publication detailing preclinical pharmacology of our clinical-stage drug candidate, NT-0249, establishing its potency and selectivity as an #NLRP3 inhibitor: https://lnkd.in/daSUf7Kb   NT-0249 has been evaluated in animal models demonstrating dose-dependent PK/PD relationships and efficacy in a mouse model of cryopyrin-associated periodic syndrome (CAPS) where it significantly reduced levels of inflammatory biomarkers including IL-1β, thus confirming in vivo target engagement.   Our findings not only underscore the pharmacological potential of NT-0249 but also shed light on the level of target suppression needed for clinical benefit.   Stay tuned for further developments as we continue to innovate for a healthier future!

We're thrilled to announce that our recent publication, "Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the #NLRP3 #Inflammasome Inhibitors NT-0249 and NT-0796," has been selected as the Editor's Choice in March's issue of the Journal of Pharmacology and Experimental Therapeutics (JPET) as well as ranked as the most read article! These recognitions underscore our commitment to groundbreaking research in combating chronic diseases linked to inflammation. Our findings pave the way for new therapeutic strategies in addressing chronic systemic #inflammation, showcasing the potential of our investigational drugs, NT-0249 and NT-0796 , as pivotal in the fight against these conditions.   A heartfelt thank you to our dedicated team and the scientific community for acknowledging our work. Together, we're making strides toward a healthier future.   Stay tuned for further updates as we continue to advance in our mission to revolutionize inflammatory disease treatment. The link to the publication: https://lnkd.in/d28K3d6D